key: cord-0265162-dw6xvgpk
authors: Berger, B.; Hazzan, M.; Kamar, N.; Francois, H.; Matignon, M.; Greze, C.; Gatault, P.; Frimat, L.; Westeel, P.-F.; Goutaudier, V.; Snanoudj, R.; Colosio, C.; Sicard, A.; Bertrand, D.; Mousson, C.; Bamoulid, J.; Thierry, A.; Anglicheau, D.; Couzi, L.; Chemouny, J. M.; Duveau, A.; Moal, V.; Le Meur, Y.; Blancho, G.; Tourret, J.; Malvezzi, P.; Mariat, C.; Rerolle, J.-P.; Bouvier, N.; the French SOT COVID Registry,; Caillard, S.; Thaunat, O.
title: Changing of therapeutic trends between the 1st and 2nd wave did not reduce COVID-19 related mortality of renal transplant recipients: a national registry study.
date: 2021-12-16
journal: nan
DOI: 10.1101/2021.12.15.21267794
sha: ea785e0ba053e5c6d5b467efc5f5b54f0fcc7a17
doc_id: 265162
cord_uid: dw6xvgpk

SARS-CoV-2 pandemic evolved in two consecutive waves over 2020 (for France: 1st wave from March 1 to July 31; and 2nd wave from August 1 to December 31). Improvements in the management of COVID-19 led to a reduction of mortality rates in hospitalized patients during the second wave. Whether this progress also benefited to kidney transplant recipients (KTR), a population particularly vulnerable to severe COVID-19, remained unclear. In France, 957 KTR were hospitalized for COVID-19 in 2020 and their data were prospectively collected in the French SOT COVID registry. The presentation, management, and outcomes of the 359 KTR diagnosed during the 1st wave were compared to those of the 598 of the 2nd wave. Baseline comorbidities were largely similar between KTR of the 2 waves. Maintenance immunosuppression was reduced in most patients but withdrawal of antimetabolite (73.7% vs 58.4%, p<0.001) or CNI (32.1% vs 16.6%, p<0.001) was less frequent during the 2nd wave. Hydroxychloroquine and azithromycin that were commonly used during the 1st wave (21.7% and 30.9%, respectively) were almost abandoned during the 2nd. In contrast, the use of high dose corticosteroids doubled (19.5% vs. 41.6%, p<0.001). Despite these changing trends in COVID-19 management, 60-day mortality was not statistically different between the 2 waves (25.3% vs. 23.9%; Log Rank, p=0.48). We conclude that changing of therapeutic trends during 2020 did not reduce COVID-19 related mortality in KTR. Our data indirectly support the importance of vaccination and monoclonal neutralizing anti-SARS-CoV-2 antibodies to protect KTR from severe COVID-19.

SARS-CoV-2 pandemic evolved in two consecutive waves over 2020 (for France: 1st wave from March 1 to July 31; and 2nd wave from August 1 to December 31).

Improvements in the management of COVID-19 led to a reduction of mortality rates in hospitalized patients during the second wave. Whether this progress also benefited to kidney transplant recipients (KTR), a population particularly vulnerable to severe COVID-19, remained unclear.

In France, 957 KTR were hospitalized for COVID-19 in 2020 and their data were prospectively collected in the French SOT COVID registry. The presentation, management, and outcomes of the 359 KTR diagnosed during the 1st wave were compared to those of the 598 of the 2nd wave. Baseline comorbidities were largely similar between KTR of the 2 waves. Maintenance immunosuppression was reduced in most patients but withdrawal of antimetabolite (73.7% vs 58.4%, p<0.001) or CNI (32.1% vs 16.6%, p<0.001) was less frequent during the 2nd wave. Hydroxychloroquine and azithromycin that were commonly used during the 1st wave (21.7% and 30.9%, respectively) were almost abandoned during the 2nd. In contrast, the use of high dose corticosteroids doubled (19.5% vs. 41.6%, p<0.001). Despite these changing trends in COVID-19 management, 60-day mortality was not statistically different between the 2 waves (25.3% vs. 23.9%; Log Rank, p=0.48).

We conclude that changing of therapeutic trends during 2020 did not reduce COVID-19 related mortality in KTR. Our data indirectly support the importance of vaccination and monoclonal neutralizing anti-SARS-CoV-2 antibodies to protect KTR from severe COVID-19.

After the initial outbreak in China in late 2019, coronavirus disease (COVID-19) spread globally 1 . As on October 14, 2021, the pandemic had affected more than 238 million people causing more than 4.8 million deaths worldwide 2 .

Like in the rest of the world 3, 4 , the viral pandemic evolved during 2020 in two consecutive waves in France. The first hit France in spring, only three months after SARS-CoV-2 discovery 5 , in a context of limited knowledge about COVID-19, absence of proven specific treatment, and shortage of essential equipment such as face masks and diagnostic tests 6, 7 . The government imposed a national lockdown from March 17, 2020 to May 10, 2020, which successfully reduced the spread of the virus and led to the resolution of this first wave 8 . However, in the absence of available vaccine, SARS-CoV-2 resurged following the ease of social distancing rules during the summer. As a result, a second pandemic wave started in fall 2020. However, in contrast with the first wave, enhanced testing capacities allowed diagnosis of asymptomatic cases during this second wave. Additionally, intensivists had better experience of the stereotypical course of severe COVID-19, including the prolonged mechanical ventilation and Intensive Care Unit (ICU) stay 9 , the increased risk of thrombotic events 10 , and the high rates of acute kidney injury 11 . More importantly, RECOVERY trial 12 had been published, providing evidence that Dexamethasone reduces mortality in hospitalized patients requiring oxygen therapy by one fifth. These changes in medical care resulted in a 10% reduction of mortality rates in French hospitalized patients during the second wave compared to the first one 13, 14 . All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. [15] [16] [17] , also benefited from the progresses made along 2020 in COVID-19 management remained unclear. Aiming at addressing this question, we retrospectively analyzed the prospectively collected data of the French Solid Organ Transplant (SOT) COVID registry and compare the course, management and outcomes of COVID-19 diagnosed in the first versus second waves in 957 hospitalized French KTR. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Of note, all patients were informed about their inclusion in the registry but the need for informed consent was waived.

Inclusion criteria were age > 18 years at the diagnosis of COVID-19 and presence of a functioning kidney graft. The diagnostic criteria for COVID-19 was based on: (i) a positive RT-PCR for SARS-CoV-2 in nasopharyngeal swab or (ii) the presence of typical respiratory symptoms accompanied by evocative pulmonary lesions on low-dose chest CT when RT-PCR yielded negative results. Cases were considered to have occurred during the 1 st wave if they were diagnosed between March 1 to July 31, 2020 and during 2 nd wave if they were diagnosed between August 1 to December 31, 2020. We used the time cutoff of December 31, 2020 for the end of the second wave to have an equal length of time compared to the first wave and to avoid the effect of the vaccination to increase baseline comparability. Cardiovascular disease included heart failure, coronary vascular disease and dysrhythmia. Respiratory disease included chronic respiratory failure, asthma and chronic obstructive pulmonary disease. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. using the "survival" and "mice" packages. All tests were 2-sided, and p<0.05 was considered statistically significant.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 16, 2021.

Shortage in diagnosis assays during the first pandemic wave resulted in the fact that only symptomatic patients were tested to confirm clinically or radiologically suspected COVID-19 21, 22 . As the result of enhanced availability of these assays along the year 2020, asymptomatic COVID-19 were identified during the second wave 21 . Furthermore, from January 2021 onward anti-SARS-CoV-2 vaccines became available, reducing the risk of severe COVID-19 and contributing to the resolution of the second pandemic wave. Since the criteria for hospitalization of KTR with symptomatic COVID-19 little evolved over time and given the fact that our aim was to compare the two pandemic waves, the present study focused on the 957 cases [n=359 (37.5%) from the first and n=598 (62.5%) from the second wave] of COVID-19 diagnosed in KTR that require hospitalization and occurred before January 1 st 2021.

The characteristics of enrolled patients, which were prospectively collected in the French SOT COVID registry, are presented in Table 1 preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The patients of the two pandemic waves were largely similar except for diabetes, the prevalence of which was slightly lower in patients of the second wave (37.3% versus 45.7% respectively; p=0.014). Difference in immunosuppression regimen were also minor with only less patients on corticosteroids (72.7% vs 81.1%, p=0.005) and mTOR inhibitors (8.9% vs 13.1%, p=0.050) in the second pandemic wave. Considering the whole cohort (Figure 1A) preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. KTR from the second wave differed from those of the first in that they less frequently exhibited fever, cough and myalgias, which could indicate earlier diagnosis during the second wave ( Figure 1B) . This hypothesis is coherent with the increased availability of diagnosis assays during the second half of 2020. However, no significant differences in CRP and PCT levels, nor in lymphocyte count could be observed between the 2 pandemic waves (data not shown). Furthermore, chest CT scan severity at presentation was also similar between the two waves with ~45%, 30% and 25% of KTR presented with mild, moderate and severe degree of involvement respectively (Figure 1C; p=0.921).

The exact impact of maintenance immunosuppression during COVID-19 is unclear 23 . On one hand these drugs could be protective against the overproduction of proinflammatory cytokines during critical COVID-19 24 ,25 , on the other solid organ transplant recipients have been found to have delayed SARS-CoV-2 clearance 26,27 .

Maintenance immunosuppression was tapered in KTR hospitalized for symptomatic COVID-19, particularly antimetabolites and mTOR inhibitors, which were discontinued in the majority of patients of both pandemic waves (Figure 2A) . However, if modifications of maintenance immunosuppression did not differ in nature between the two waves, they were made in a smaller proportion of patients during the second wave, particularly regarding withdrawal of CNI (32.1% vs 16.6%, p<0.001) and of antimetabolites (73.7% vs 58.4%, p<0.001; Figure 2A) , which is in line with a previous report from the USA 28 . All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Contrasting with the global stability of immunosuppression management, anti-SARS-CoV-2 therapies differed in many respects between the two waves ( Figure 2B) . KTR with COVID-19 from the second wave received less frequently probabilistic antibiotics compared to those of the first wave (75.8% vs 49.2%, p<0.001). Hydroxychloroquine and azithromycin, which were commonly used during the first wave were almost completely abandoned during the second (21.7% vs 1.7% and 30.9% vs 5.0%, p<0.001, respectively). Tocilizumab use declined between the first and second waves (7.5% vs 2.2%, p<0.001). Conversely, the use of high dose corticosteroids doubled (19.5% vs. 41 .6%, p<0.001).

Univariate analysis conducted on the whole cohort identified: age, hypertension, preexisting cardiovascular disease, history of cancer, diabetes, dyspnea at admission, CRP > 60 mg/L at admission, baseline eGFR as significantly associated with mortality (data not shown). In contrast, diarrhea, anosmia and headaches were associated with reduced risk of death.

In multivariable analysis, only age>50 years, history of cancer, dyspnea or CRP > 60 mg/L at admission, and baseline eGFR<30ml/min/m² remained independently associated with a higher risk of death in KTR hospitalized for COVID-19 (Figure 3) , while anosmia at admission was associated with a better prognosis (Figure 3) .

The incidence of thromboembolic events (9.5% vs 6.4%, p=0.135) and bacterial superinfection (27.0% vs 30.7%, p=0.304) was similar between the 2 pandemic waves.

A non-significant trend for lesser use of RRT (15.9% vs 12.9%, p=0.230), mechanical ventilation (26.5% vs 22.1%, p=0.152) and vasopressor support (20.5% vs 15.9%, All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.15.21267794 doi: medRxiv preprint p=0.304) was observed during the 2 nd wave but mortality at 60 days from admission (24.5%) was in the range of what previously reported 29,30 , with no significant difference between the first and second wave (Figure 4A ; Log rank test, p=0.48).

A slight difference in dynamic between the two waves could however be observed on Kaplan Meier curves (Figure 4A) , with shorter delay between admission and death due to COVID-19 in KTR of the first wave (death at 14 days: 16.7% vs 10.1%, p=0.002). This difference is to be interpreted together with a faster and higher incidence of transfer in ICU for patients of the first wave ( Figure 4B) , without difference on the mortality for patients transferred in ICU ( Figure 4C) . Altogether, these findings could indicate that patients of the first wave were diagnosed (and therefore hospitalized) later in the course of COVID-19, a hypothesis in line with the difference in clinical presentation between the 2 waves reported above ( Figure 1B) .

In contrast with the second wave that impacted the entire French territory, the first pandemic wave had a heterogeneous geographic distribution 31 that could have introduce a "learning-curve" bias. Physicians from the geographic area impacted by the first wave could have accumulated knowledge and skills useful to better manage patients from the second wave. To test this hypothesis, we compared the survival of KTR hospitalized for COVID-19 during the second wave in geographic area impacted (in red on the map Figure 4D ) vs preserved (in green on the map Figure 4D ) during the first pandemic wave. The similarity in survival for patients of the second wave hospitalized in either of these two areas strongly argue against the theory of the learning curve bias (Figure 4E ). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Kidney transplant recipients (KTR), who are characterized by a highly comorbid profile and receive therapeutic immunosuppression to prevent graft rejection, were very early identified as particularly vulnerable to COVID-19 [15] [16] [17] . An excess of mortality, integrally explained by COVID-19, was indeed reported in this population during the first wave of the pandemic in France 31 and several large multicenter cohorts KTR estimated shortterm intra-hospital mortality around 20-32% 29,32,33 . Among the risk factors identified in previous publications for death due to COVID-19 in KTR are age, eGFR and presence of comorbidities, including cardiovascular disease, diabetes, and/or obesity 31,32,34,35 .

Additionally, dyspnea and elevations of biochemical markers of inflammation at diagnosis of COVID-19 were also associated with less favorable survival figures [36] [37] [38] .

Our study largely confirms these data. In addition, it provides original additional information regarding the stability of the risk of death due to COVID-19 in KTR, despite the impressive accumulation of knowledge regarding the disease, which translated in better outcomes in the general population 13, 14, 39 . Indeed, despite a more homogeneous COVID-19 management with wider prescription of Dexamethasone and important decrease in the use of treatments deemed inefficient such as azithromycin 40 , hydroxychloroquine 40, 41 , lopinavir/ritonavir 42 , survival of hospitalized KTR during the second wave remained similar to that observed during the first wave. Our findings concur with a meta-analysis including 5559 KTR with COVID-19 that reported a mean mortality rate of 23% (similar to what we observed) without significant difference between "early" (studies submitted before July 2020) and "late" (studies submitted from July 2020 onwards) phases of the pandemic 43 . These conclusions conflict with a recent All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 28 . In their report, crude mortality by 28 days indeed declined from 19.6% in early period to 13.7% in late period and after adjusting for differences in baseline comorbidities between both periods, the odds of death remained lower in the late period (aOR 0.67, 95% CI 0.46 -0.98, p = 0.04). Instead of the changing trends in management of COVID-19 patients, we believe that the observations made by Heldman et al, could be explained by the numerous differences in the baseline comorbid profiles of SOTR between the early and late period (SOTR in late period presented with less hypertension, diabetes, heart failure, coronary artery disease, chronic lung disease) and/or by the short follow-up period of the study.

Indeed, when we assessed 14-days mortality in our own cohort, we also found a significant difference between the first and second wave (16.7% vs. 10.1%, p-value = 0.002, respectively) that progressively disappeared by the end of the 60-days follow-up period. Whether this effect is attributable to earlier diagnosis of COVID-19 in KTR during the second wave is possible and supported by some clues discussed above but remains to be formerly demonstrated.

Among the strengths of our study are the relative high number of patients enrolled and the prospective collection of data. Our study has however also some limitations. First, we compared two periods (first and second wave) but did not take into account COVID-19 ICU occupancy rates, a factor thought to impact on mortality rates 13 . Second, our study was not designed to capture the impact of vaccines, which only became available early 2021. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Accumulating evidence suggests however that KTR have an impaired response to the "standard" 2-dose of mRNA vaccine 44-47 , which leaves them at high risk of severe COVID-19 46,48 . Despite intensified scheme of vaccination (with third and even a fourth vaccine dose now recommended in weak responders), up to 20% of KTR will not develop sufficient protection against COVID-19 [49] [50] [51] . In this regard, the development of monoclonal neutralizing anti-SARS-CoV-2 Spike Protein Antibodies represent an interesting therapeutic option. The latter are already available in high-risk patients diagnosed with mild to moderate COVID-19 52 (post-exposition therapy) and first reports about their use for prophylaxis (pre-exposition therapy) are promising 53 .

In conclusion, changing of therapeutic trends during 2020 did not reduce COVID-19 related mortality in KTR. Our data thus indirectly stress the importance of therapeutic progresses made during 2021, including vaccination and monoclonal neutralizing anti-SARS-CoV-2 spike protein antibodies, to protect this vulnerable population from death due to COVID-19.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.15.21267794 doi: medRxiv preprint

All the authors declared no competing interests. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CV, cardiovascular; RAS, renin-angiotensin-system; eGFR, estimated glomerular filtration rate; anti-IL2R, anti-interleukin-2 receptor; ATG, anti-thymocyte globulin; CNI, calcineurin inhibitor; mTor, mechanistic target of rapamycin. Baseline eGFR is determined with the MDRD equation.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations are: CRP, C-reactive protein; PCT, procalcitonin; SCr, serum creatinine. χ 2 test; p>0.05, ns.

Comparison of the management of immunosuppression (A) and the use of COVID-19 specific treatments (B) between the 1 st (blue) vs 2 nd (red) pandemic wave.

Abbreviations are: CNI, calcineurin inhibitor; mTor, mechanistic target of rapamycin; ATB, antibiotics. χ 2 test; p>0.05, ns.

This forest plot shows the variable independently associated with the risk of death in multivariate analysis for the 957 KTR diagnosed with COVID-19 during the 1 st or the 2 nd pandemic wave. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

A In-hospital survival of KTR diagnosed with COVID-19 during the 1 st and 2 nd wave. Comparison were made using the Log Rank test. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Characteristics of SARS-CoV-2 and COVID-19

COVID-19) Situation Reports

Characteristics and Outcomes of COVID-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area

Main differences between the first and second waves of COVID-19 in Madrid, Spain

A Novel Coronavirus from Patients with Pneumonia in China

Considerations for diagnostic COVID-19 tests

Electronic address: martin.hirsch@aphp.fr. Assistance Publique-Hôpitaux de Paris' response to the COVID-19 pandemic

Impact of Lockdown on the Epidemic Dynamics of COVID-19 in France

Pathogenesis of COVID-19-induced ARDS: implications for an ageing population

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19

Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance data analysis

A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia

Covid-19 and Kidney Transplantation

Factors associated with COVID-19-related death using OpenSAFELY

Multivariate Imputation by Chained Equations in R

Laboratory Diagnosis of SARS-CoV-2 Pneumonia

Signes cliniques d'orientation diagnostique du Covid-19. Haut Conseil de la Santé Publique

Is COVID-19 infection more severe in kidney transplant recipients?

COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities

High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study

Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant Recipients

Trends Over Time in the Risk of Adverse Outcomes Among Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials

A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: Lessons to be learned

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

COVID-19 vaccination in kidney transplant recipients

Occurrence of severe COVID-19 in vaccinated transplant patients

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

on behalf of the French-speaking Society of Transplantation. Antibody response to a fourth mRNA Covid-19 vaccine boost in weak responder kidney transplant recipients. medRxiv

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 | NEJM

The French SOT COVID Registry Collaborators are as follows: Sophie Caillard

Service de Néphrologie

Service de Néphrologie

Service de Néphrologie, Tours; Jean-François Augusto

Service de Néphrologie, Hôpital Maison Blanche, Reims; Paolo Malvezzi

Service de Néphrologie, Hémodialyse et Transplantation Rénale

Service de Néphrologie−Transplantation−Dialyse

Service d'Hépatologie, Hôpital Foch, Suresnes; Sébastien Dharancy, Service d'Hépatologie, Hôpital Huriez, Lille; Éphrem Salame, Service de Chirurgie Hépatique

OT is supported by the Etablissement Français du Sang and the Fondation pour la Recherche Médicale (PME20180639518). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this this version posted December 16, 2021.